89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio announced the approval of non-qualified stock options to purchase 49,800 shares of common stock granted to four new employees on November 25, 2024. These Inducement Grants, made under the company's 2023 Inducement Plan, were approved by the Compensation Committee and align with Nasdaq Listing Rule 5635(c)(4). The options' exercise price equals the closing price on the grant date and will vest over four years, with 25% vesting after one year and the remainder vesting in 12 quarterly installments, contingent on continued employment.
89bio ha annunciato l'approvazione di opzioni azionarie non qualificate per l'acquisto di 49.800 azioni ordinarie, concesse a quattro nuovi dipendenti il 25 novembre 2024. Questi Inducement Grants, effettuati ai sensi del Piano di Inducimento 2023 dell'azienda, sono stati approvati dal Comitato per la Retribuzione e sono in linea con la Regola 5635(c)(4) della Nasdaq. Il prezzo di esercizio delle opzioni corrisponde al prezzo di chiusura alla data di concessione e maturerà in quattro anni, con il 25% che matura dopo un anno e il resto che matura in 12 rate trimestrali, subordinatamente a un impiego continuato.
89bio anunció la aprobación de opciones de acciones no calificadas para comprar 49,800 acciones ordinarias concedidas a cuatro nuevos empleados el 25 de noviembre de 2024. Estas Concesiones por Inducimiento, realizadas bajo el Plan de Inducimiento 2023 de la empresa, fueron aprobadas por el Comité de Compensación y están en consonancia con la Regla 5635(c)(4) de Nasdaq. El precio de ejercicio de las opciones es igual al precio de cierre en la fecha de concesión y se consolidará en cuatro años, con el 25% consolidándose después de un año y el resto consolidándose en 12 trimestres, condicionado a la continuación del empleo.
89bio는 2024년 11월 25일에 네 명의 신입 사원에게 49,800주를 구매할 수 있는 비자격 주식 옵션의 승인을 발표했습니다. 이 유도 보상은 회사의 2023 유도 계획에 따라 이루어졌으며, 보상 위원회에 의해 승인되었고 Nasdaq 상장 규칙 5635(c)(4)에 부합합니다. 옵션의 행사 가격은 부여일의 종가와 같으며 4년에 걸쳐 분할 vesting되며, 1년 후 25%가 vesting되고 나머지는 계속 고용 조건에 따라 12개의 분기별 할부로 vesting됩니다.
89bio a annoncé l'approbation de stock-options non qualifiées permettant d'acheter 49 800 actions ordinaires accordées à quatre nouveaux employés le 25 novembre 2024. Ces Attributions d'Inducement, réalisées dans le cadre du Plan d'Inducement 2023 de l'entreprise, ont été approuvées par le Comité de Rémunération et sont conformes à la Règle de Cotation 5635(c)(4) du Nasdaq. Le prix d'exercice des options est égal au prix de clôture à la date de l'attribution et sera acquis sur quatre ans, avec 25 % acquis après un an et le reste acquis en 12 versements trimestriels, soumis à une poursuite de l'emploi.
89bio gab die Genehmigung von nicht qualifizierten Aktienoptionen zum Kauf von 49.800 Stammaktien bekannt, die am 25. November 2024 vier neuen Mitarbeitern gewährt wurden. Diese Anreizgewährungen, die im Rahmen des Unternehmensplans von 2023 erfolgen, wurden vom Vergütungsausschuss genehmigt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Der Ausübungspreis der Optionen entspricht dem Schlusskurs am Gewährungstag und wird über vier Jahre einstehen, wobei 25 % nach einem Jahr einstehen und der Rest in 12 vierteljährlichen Raten, abhängig von der fortgesetzten Beschäftigung.
- Employee retention strategy implemented through stock options grants
- Structured vesting schedule promotes long-term employee commitment
- Potential future dilution of existing shareholders through stock options
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,800 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on November 25, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
How many shares were included in 89bio's (ETNB) November 2024 inducement grants?
What is the vesting schedule for 89bio's (ETNB) November 2024 inducement grants?
When did 89bio (ETNB) approve the November 2024 inducement grants?
